Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Cash (2016 - 2025)

Fate Therapeutics' Change in Cash history spans 14 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 424.12% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $10.6 million, up 198.22%, while the annual FY2025 figure was $10.6 million, 198.22% up from the prior year.
  • Change in Cash reached $6.0 million in Q4 2025 per FATE's latest filing, up from -$627000.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $79.5 million in Q1 2024 to a low of -$84.4 million in Q2 2024.
  • Average Change in Cash over 5 years is -$6.3 million, with a median of -$2.8 million recorded in 2024.
  • Peak YoY movement for Change in Cash: tumbled 4108.15% in 2021, then skyrocketed 511.39% in 2024.
  • A 5-year view of Change in Cash shows it stood at $4.4 million in 2021, then tumbled by 571.5% to -$20.8 million in 2022, then soared by 141.12% to $8.5 million in 2023, then tumbled by 121.71% to -$1.9 million in 2024, then soared by 424.12% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Change in Cash are $6.0 million (Q4 2025), -$627000.0 (Q3 2025), and -$3.7 million (Q2 2025).